Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA has granted orphan drug designation to OCT-980, an oral treatment being developed for rhodopsin-associated autosomal dominant retinitis pigmentosa, according to a press release from Octant Bio.
The drug is designed to correct the accumulation of misfolded rhodopsin proteins in the retina, which leads to vision loss, according to the company.
“People with [rhodopsin-associated autosomal dominant retinitis pigmentosa] are living with progressive vision loss and no approved treatment options today,”